抗胸腺细胞球蛋白用于血液系统恶性肿瘤患者同胞全合供者移植:一项多中心、开放标签、随机对照研究
在中国23个移植中心开展的前瞻性随机对照试验纳入263例40-60岁标危血液系统恶性肿瘤且具有HLA全合同胞供者的患者,随机分为ATG组(4.5 mg/kg兔抗胸腺细胞球蛋白联合环孢素、甲氨蝶呤、吗替麦考酚酯)和对照组(环孢素、甲氨蝶呤、吗替麦考酚酯)。ATG组第100天2-4级急性GVHD累积发生率显著低于对照组(13.7% vs 27.0%,P=0.007),2年广泛型慢性GVHD(8.5% vs 23.2%,P=0.029)及3年无GVHD无复发生存(38.7% vs 24.5%,P=0.003)均显著改善,而巨细胞病毒再激活、EB病毒再激活、3年非复发死亡、3年累积复发率、3年总生存及3年无白血病生存两组无差异。
要点
- ATG组第100天2-4级aGVHD累积发生率为13.7%,显著低于对照组的27.0%(P=0.007)。
- ATG组2年广泛型cGVHD发生率为8.5%,显著低于对照组的23.2%(P=0.029)。
- 两组3年非复发死亡、累积复发率、总生存及无白血病生存均无差异。
核心结论
- ATG可有效降低环孢素时代同胞全合供者移植后急性GVHD发生率,且不影响累积复发率或非复发死亡。
研究设计与样本
- 前瞻性、多中心、开放标签、随机对照试验,在中国23个移植中心开展。
- 纳入40-60岁标危血液系统恶性肿瘤且具有HLA全合同胞供者的患者263例。
- 随机分为ATG组(4.5 mg/kg兔抗胸腺细胞球蛋白联合环孢素、甲氨蝶呤、吗替麦考酚酯)和对照组(环孢素、甲氨蝶呤、吗替麦考酚酯)。
- 主要终点为第100天2-4级急性GVHD。
主要发现
- 第100天2-4级aGVHD累积发生率ATG组为13.7%(95%CI 13.5%-13.9%),对照组为27.0%(95%CI 26.7%-27.3%),P=0.007。
- 2年总体cGVHD发生率ATG组为27.9%(95%CI 27.6%-28.2%),对照组为52.5%(95%CI 52.1%-52.9%),P<0.001。
- 2年广泛型cGVHD发生率ATG组为8.5%(95%CI 8.4%-8.6%),对照组为23.2%(95%CI 22.9%-23.5%),P=0.029。
- 3年无GVHD无复发生存率ATG组为38.7%(95%CI 29.9%-47.5%),对照组为24.5%(95%CI 16.9%-32.1%),P=0.003。
- 巨细胞病毒再激活、EB病毒再激活、3年非复发死亡、3年累积复发率、3年总生存及3年无白血病生存两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of antithymocyte globulin (ATG) in preventing acute graft-versus-host disease (aGVHD) after HLA-matched sibling donor transplantation (MSDT) is still controversial. PATIENTS AND METHODS: We performed a prospective, multicenter, open-label, randomized controlled trial (RCT) across 23 transplantation centers in China. Patients ages 40-60 years with standard-risk hematologic malignancies with an HLA-matched sibling donor were randomly assigned to an ATG group (4.5 mg/kg thymoglobulin plus cyclosporine [CsA], methotrexate [MTX], and mycophenolate mofetil [MMF]) and a control group (CsA, MTX, and MMF). The primary end point of this study was grade 2-4 aGVHD on day 100. RESULTS: From November 2013 to April 2018, 263 patients were enrolled. The cumulative incidence rate of grade 2-4 aGVHD was significantly reduced in the ATG group (13.7%; 95% CI, 13.5% to 13.9%) compared with the control group (27.0%; 95% CI, 26.7% to 27.3%; P = .007). The ATG group had significantly lower incidences of 2-year overall chronic GVHD (27.9% [95% CI, 27.6% to 28.2%] v 52.5% [95% CI, 52.1% to 52.9%]; P < .001) and 2-year extensive chronic GVHD (8.5% [95% CI, 8.4% to 8.6%] v 23.2% [95% CI, 22.9% to 23.5%]; P = .029) than the control group. There were no differences between the ATG and control groups with regard to cytomegalovirus reactivation, Epstein-Barr virus reactivation, 3-year nonrelapse mortality (NRM), 3-year cumulative incidence of relapse (CIR), 3-year overall survival, or 3-year leukemia-free survival. Three-year GVHD relapse-free survival was significantly improved in the ATG group (38.7%; 95% CI, 29.9% to 47.5%) compared with the control group (24.5%; 95% CI, 16.9% to 32.1%; P = .003). CONCLUSION: Our study is the first prospective RCT in our knowledge to demonstrate that ATG can effectively decrease the incidence of aGVHD after MSDT in the CsA era without affecting the CIR or NRM.
引用
- Chang YJ, Wu DP, Lai YR, et al. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. J Clin Oncol. 2020. PMID: 32650683. doi:10.1200/JCO.20.00150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。